viral
fusion
protein
mediat
cell
entri
undergo
seri
conform
chang
result
viriontarget
cell
membran
fusion
class
viral
fusion
protein
encod
influenza
viru
human
immunodefici
viru
hiv
contain
two
promin
alpha
helic
peptid
mimic
portion
alpha
helic
inhibit
structur
rearrang
fusion
protein
prevent
viral
infect
envelop
glycoprotein
e
flavivirus
west
nile
viru
wnv
dengu
viru
denv
class
ii
viral
fusion
protein
compris
predominantli
beta
sheet
use
physiochem
algorithm
wimleywhit
interfaci
hydrophob
scale
wwih
combin
known
structur
data
identifi
potenti
peptid
inhibitor
wnv
denv
infect
target
viral
e
protein
viral
inhibit
assay
confirm
sever
peptid
specif
interfer
target
viru
entri
inhibitori
concentr
rang
inhibitori
peptid
similar
sequenc
domain
signific
wwih
score
includ
domain
ii
iib
stem
domain
detect
peptid
correspond
stem
domain
denv
inhibit
infect
denv
inhibit
plaqu
format
concentr
crossinhibit
wnv
fusioninfect
inhibit
also
demonstr
howev
potent
wnv
inhibitori
peptid
correspond
wnv
e
domain
iib
inhibit
infect
denv
addit
result
suggest
inhibitori
peptid
noncytotox
act
sequenc
specif
manner
inhibitori
peptid
identifi
serv
lead
compound
develop
peptid
drug
flaviviru
infect
envelop
virus
util
membranebound
fusion
protein
mediat
attach
entri
specif
target
host
cell
virion
assembl
process
newli
synthes
envelop
protein
target
endoplasm
reticulum
golgi
apparatu
initi
fold
posttranscript
process
occur
includ
multimer
glycosyl
proteolysi
initi
fold
process
requir
achiev
conform
protein
held
metast
state
prior
virion
releas
post
virion
releas
multimer
envelop
protein
pois
undergo
structur
rearrang
lead
fusion
virion
new
target
cell
lipid
bilay
membran
depend
viru
system
rearrang
trigger
take
form
specif
receptor
bind
multipl
receptor
bind
decreas
ph
follow
receptor
mediat
endocytosi
combin
trigger
prototyp
viral
envelop
fusion
protein
hemagglutinin
influenza
viru
contain
short
alpha
helic
domain
trimer
virion
configur
respons
receptor
bind
decreas
ph
short
helic
rearrang
adjoin
sequenc
produc
longer
helix
thu
expos
ntermin
fusion
peptid
believ
interact
directli
target
cell
membran
follow
hingelik
bend
entir
complex
adjoin
fuse
two
lipid
membran
structur
rearrang
result
extrus
fusion
peptid
subsequ
collaps
involv
alter
pack
region
within
individu
fusion
protein
well
monomer
subunit
trimer
structur
sever
dispar
virus
includ
arenavirus
coronavirus
filovirus
orthomyxovirus
paramyxovirus
retrovirus
encod
similar
protein
togeth
classifi
class
fusion
protein
class
viral
fusion
protein
vari
length
sequenc
similar
overal
structur
qureshi
et
al
demonstr
peptid
one
two
extend
helic
domain
transmembran
protein
block
virion
infect
subsequ
fda
approv
drug
aka
enfuvirtid
nand
chelix
inhibitori
peptid
develop
result
greatli
motiv
search
inhibitori
peptid
addit
peptid
mimic
fusion
protein
retrovirus
orthomyxovirus
paramyxovirus
filovirus
coronavirus
herpesvirus
also
identifi
shown
inhibit
viral
entri
envelop
fusion
protein
sever
viru
type
includ
flavivirus
alphavirus
structur
distinct
class
viral
fusion
protein
envelop
glycoprotein
e
flaviviru
tickborn
enceph
viru
tbev
consist
three
domain
structur
central
amino
termin
domain
domain
dimer
domain
domain
ii
carboxyl
termin
iglik
domain
domain
iii
contain
predominantli
beta
sheet
fold
primari
sequenc
fusion
protein
semliki
forest
viru
alphaviru
reveal
remark
fit
scaffold
tbev
e
suggest
exist
second
class
viral
fusion
protein
dengu
viru
denv
e
protein
also
shown
class
ii
structur
recent
studi
flaviviru
virion
protein
cryoelectron
microscopi
crystal
structur
analysi
lead
greatli
increas
understand
function
class
ii
viral
envelop
protein
includ
structur
rearrang
undergo
matur
trigger
fusion
flavivirus
includ
denv
west
nile
viru
wnv
yellow
fever
viru
japanes
enceph
viru
jev
tbev
among
other
transmit
vertebr
host
insect
vector
seriou
manifest
denv
infect
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
four
serotyp
denv
togeth
caus
estim
million
human
infect
per
year
caus
df
dhf
dss
phenomenon
antibodydepend
enhanc
ade
immun
phenomena
protect
one
denv
serotyp
increas
risk
dhf
dss
individu
expos
anoth
serotyp
crossreact
nonneutr
antibodi
mediat
entri
denv
macrophag
dendrit
cell
viral
target
cell
via
fc
receptor
increas
viru
titer
thu
patholog
multival
denv
vaccin
shown
promis
human
nonhuman
primat
studi
face
sever
obstacl
antivir
drug
target
four
serotyp
denv
without
enhanc
pathogenesi
serotyp
urgent
need
recent
introduct
wnv
unit
state
highlight
public
health
challeng
pose
flavivirus
effect
vaccin
antivir
drug
therapi
current
avail
either
denv
wnv
although
mani
differ
structur
class
class
ii
viral
fusion
protein
hypothes
function
similar
membran
fusion
mechan
involv
rearrang
domain
peptid
mimick
portion
class
ii
viral
fusion
protein
would
inhibit
virion
fusion
entri
step
therebi
serv
lead
compound
develop
antivir
use
physiochem
algorithm
wimleywhit
interfaci
hydrophob
scale
combin
known
structur
data
predict
region
denv
wnv
e
protein
may
play
role
proteinprotein
rearrang
bilay
membran
interact
entri
fusion
process
sever
peptid
specif
inhibit
denv
wnv
infect
domain
preced
transmembran
anchor
class
fusion
protein
highli
hydrophob
howev
usual
contain
cluster
aromat
amino
acid
display
tendenc
partit
bilay
membran
reveal
analys
use
experimentallydetermin
wimleywhit
interfaci
hydrophob
scale
wwih
fuzeon
correspond
sequenc
overlap
aromat
preanchor
domain
tm
synthet
peptid
correspond
domain
class
viral
fusion
protein
signific
wwih
score
may
also
inhibit
viral
infect
previous
suggest
peptid
drug
analog
fuzeon
might
develop
hcv
member
flavivirida
denv
e
contain
five
domain
signific
wwih
score
fig
wwih
sequenc
black
includ
fusion
peptid
domain
portion
subdomain
iib
preanchor
stem
region
follow
domain
iii
transmembran
domain
sequenc
high
wwih
score
similarli
locat
xray
structur
wnv
e
alphaviru
sfv
sindbi
viru
sinv
potenti
also
put
class
ii
fusion
protein
hepat
c
viru
hcv
pestivirus
bunyavirus
region
high
wwih
score
predict
play
role
proteinprotein
interact
structur
rearrang
proteinlipid
interact
bilay
fusion
predict
synthet
peptid
correspond
region
may
potenti
inhibit
flaviviru
infect
test
hypothesi
initi
set
synthet
peptid
repres
sequenc
denv
e
wnv
e
signific
wwih
score
synthes
screen
diagramat
structur
denv
envelop
protein
show
inhibitori
peptid
region
abil
inhibit
plaqu
format
flavivirus
tabl
peptid
correspond
transmembran
domain
test
region
expos
entri
process
initi
assay
inhibitori
activ
perform
use
highest
concentr
peptid
could
obtain
aqueou
solut
maximum
dmso
plaqu
reduct
inhibitor
remov
viru
adsorpt
stringent
test
antivir
agent
prior
initi
studi
develop
new
immunoplaqu
assay
denv
wnv
approxim
focu
form
unit
ffu
either
wnv
denv
preincub
peptid
use
infect
monolay
monkey
kidney
epitheli
cell
number
result
viral
foci
determin
three
experi
normal
plaqu
inhibit
assay
nopeptid
control
calcul
percent
inhibit
screen
initi
set
detect
sever
peptid
abl
inhibit
infect
denv
wnv
tabl
fig
peptid
similar
sequenc
domain
signific
wwih
score
includ
domain
ii
iib
stem
domain
found
inhibitori
activ
doserespons
curv
determin
potent
peptid
wnv
also
peptid
denv
fig
peptid
show
maximum
inhibitori
activ
wnv
mean
sd
inhibitori
activ
decreas
decreas
concentr
inhibitori
concentr
roughli
peptid
show
maximum
inhibitori
activ
wnv
inhibitori
activ
decreas
decreas
concentr
roughli
peptid
show
maximum
inhibitori
activ
denv
inhibitori
activ
decreas
decreas
concentr
roughli
denv
stem
peptid
wnv
peptid
reproduc
inhibit
infect
low
concentr
peptid
match
preanchor
domain
sequenc
highli
conserv
among
insecttransmit
flavivirus
inhibit
infect
denv
inhibit
plaqu
format
concentr
crossinhibit
wnv
fusioninfect
inhibit
also
reproduc
demonstr
fig
howev
wnv
inhibitori
peptid
inhibit
infect
denv
determin
peptid
specif
inhibit
infect
virus
design
peptid
test
inhibitori
effect
sindbi
viru
sinv
alphaviru
encod
class
ii
fusion
protein
none
peptid
show
statist
signific
effect
sinv
infect
fig
peptid
amino
acid
composit
scrambl
sequenc
scrambl
vatwhldwsrefplflmn
scrambl
yfidtsgaiwgashltgvlfdfmgiqggavlak
synthes
test
abil
inhibit
infect
wnv
denv
respect
neither
scrambl
peptid
significantli
inhibit
infect
virus
fig
result
provid
evid
action
inhibitori
peptid
due
gener
inactiv
envelop
virion
sequenc
specif
doserespons
curv
peptid
possibl
inhibitori
peptid
induc
cellular
alter
toxic
block
flaviviru
entri
step
replic
cycl
address
possibl
monkey
kidney
epitheli
cell
monolay
expos
mgml
concentr
peptid
hr
cell
viabil
assay
mtt
assay
statist
differ
observ
viabil
control
cell
versu
cell
expos
peptid
dmso
fig
result
suggest
inhibitori
peptid
block
infect
via
effect
host
cell
metabol
viabil
ad
combin
peptid
block
entri
differ
step
target
differ
domain
may
produc
greater
inhibit
infect
either
peptid
alon
synergist
antagonist
effect
also
possibl
peptid
alter
proteinprotein
interact
allow
greater
lesser
access
e
domain
target
anoth
peptid
sinc
peptid
inhibit
wnv
entri
possibl
antagonist
synergist
function
examin
test
alon
combin
three
concentr
three
concentr
peptid
combin
effect
alon
less
effect
alon
indic
activ
peptid
antagonist
effect
function
peptid
fig
synthet
peptid
correspond
sequenc
denv
wnv
e
protein
identifi
inhibit
infect
viral
pathogen
major
public
health
import
inhibitori
effect
peptid
dose
depend
rang
sever
potent
peptid
show
inhibitori
activ
sinv
alphaviru
possess
class
ii
viral
fusion
protein
similar
overal
structur
flaviviru
e
scrambl
peptid
amino
acid
composit
inhibitori
peptid
differ
primari
sequenc
fail
inhibit
denv
wnv
infect
none
denv
wnv
inhibitori
peptid
induc
gross
cytopath
effect
kill
cultur
cell
show
evid
vitro
cellular
toxic
result
indic
inhibitori
peptid
function
sequencespecif
mechan
mere
cytotox
figur
effect
denv
wnv
specif
peptid
anoth
viru
peptid
concentr
test
inhibitori
activ
alphaviru
sinv
similar
plaqu
reduct
assay
result
shown
mean
three
trial
sem
none
peptid
show
statist
signific
inhibitori
effect
sinv
anova
p
dunnett
posthoc
test
effect
scrambl
peptid
order
inhibitori
function
figur
effect
scrambl
peptid
order
inhibitori
function
scrambl
version
peptid
concentr
test
inhibitori
effect
denv
wnv
respect
scrambl
version
peptid
show
inhibitori
activ
compar
origin
peptid
membran
fusion
class
ii
viral
fusion
protein
initi
interact
fusion
peptid
target
cell
membran
class
viral
fusion
protein
subsequ
rearrang
trimer
protein
two
helic
form
sixhelix
bundl
bring
viral
cell
membran
closer
proxim
inhibitor
virus
class
fusion
protein
mimic
portion
one
two
helic
interfer
step
proxim
sixhelix
bundl
format
possibl
form
inact
aggreg
opposit
helix
recent
studi
indic
insert
fusion
peptid
class
ii
viral
fusion
protein
likewis
undergo
rearrang
case
intraprotein
interact
may
occur
stem
domain
domain
ii
andor
iii
accord
model
viral
cellular
membran
brought
closer
interact
stem
portion
e
result
bilay
fusion
peptid
may
interfer
intramolecular
interact
stem
portion
class
ii
viral
fusion
protein
possibl
suggest
previous
two
inhibitori
peptid
design
overlap
region
e
protein
domain
iii
junction
specif
inhibitori
wnv
recent
investig
hypothes
small
molecul
inhibitor
domain
iii
junction
region
might
develop
modi
et
al
predict
interact
near
region
kl
loop
involv
rotat
chang
domain
might
block
small
molecul
inhibitor
howev
similar
peptid
design
analog
region
denv
e
protein
fail
inhibit
denv
infect
possibl
interact
target
cell
surfac
compon
exert
inhibitori
effect
rule
howev
major
flaviviru
neutral
antibodi
appear
involv
receptor
block
bind
domain
iii
solubl
domain
iii
block
flaviviru
entri
appar
competit
cellular
receptor
contrast
domain
correspond
peptid
iib
preanchor
stem
appear
involv
structur
rearrang
fusion
rather
direct
interact
cellular
receptor
interestingli
previou
observ
indic
monoclon
antibodi
block
virion
entri
post
attach
step
indic
may
interfer
conform
chang
necessari
fusion
possibl
antibodi
gain
access
region
import
conform
chang
block
chang
suggest
inhibitori
peptid
region
might
candid
novel
vaccin
design
either
inhibitori
effect
peptid
alon
combin
figur
inhibitori
effect
peptid
alon
combin
peptid
test
alon
alon
alon
togeth
wnv
inhibitori
activ
three
concentr
measur
mean
three
trial
sd
shown
togeth
effect
intermedi
two
peptid
alon
util
inhibitori
peptid
region
directli
antigen
target
region
interact
inhibitori
peptid
studi
need
defin
exact
mechan
inhibit
denv
wnv
peptid
specif
natur
locat
interact
viral
target
peptid
inhibitori
denv
well
wnv
correspond
preanchor
region
highli
conserv
denv
wnv
well
among
flavivirus
tabl
probabl
function
similar
manner
entri
flavivirus
thu
similar
peptid
may
act
broadspectrum
flaviviru
inhibitor
flavivirus
consid
potenti
bioterror
agent
includ
jev
kyasanur
forest
diseas
viru
tbev
may
also
inhibit
deriv
analog
peptid
unlik
propos
denv
vaccin
must
multival
ie
simultan
effect
four
denv
serotyp
phenomenon
antibodi
depend
enhanc
peptid
drug
target
highli
conserv
stem
conserv
motif
flaviviru
e
may
demonstr
crossstrain
efficaci
rang
consid
promis
class
viral
fusion
protein
inhibitor
develop
thu
peptid
identifi
serv
lead
compound
may
develop
peptid
drug
four
serotyp
denv
wnv
potenti
flavivirus
anticip
peptid
inhibitor
may
success
inhibitori
peptid
unlik
persist
hiv
infect
immun
respons
denv
flavivirus
capabl
clear
virus
individu
surviv
initi
infect
reduc
viral
load
initi
stage
infect
may
possibl
extend
window
time
immun
respons
could
aris
thu
enabl
individu
control
elimin
surviv
infect
agent
evid
abil
therapeut
interven
flavivirusinduc
diseas
demonstr
recent
observ
administr
neutral
antibodi
wnv
cur
even
symptom
initi
develop
resist
mutant
concern
less
problemat
case
longterm
treatment
persist
retrovir
infect
worth
note
hiv
inhibitor
initi
identifi
use
predict
strategi
without
avail
structur
data
fact
develop
peptid
use
predict
algorithm
valid
approach
well
accuraci
flaviviru
e
protein
structur
data
similar
approach
may
use
larg
number
virus
class
ii
envelop
fusion
protein
without
known
structur
sequenc
denv
wnv
e
posit
wimleywhit
interfaci
hydrophob
scale
score
determin
use
program
membran
protein
explor
consider
known
secondari
structur
sever
subdomain
e
select
peptid
synthes
solidphas
convent
chemistri
genem
synthesi
san
francisco
ca
peptid
purifi
reversephas
high
perform
liquid
chromatographi
confirm
amino
acid
analysi
electrospray
mass
spectrometri
peptid
stock
solut
prepar
viral
plaqu
reduct
assay
target
cell
seed
densiti
cell
well
plate
h
prior
infect
approxim
form
unit
ffu
denv
wnv
sinvegfp
incub
without
peptid
serumfre
dmem
h
rt
viruspeptid
viruscontrol
mixtur
allow
infect
confluent
monolay
h
time
medium
remov
cell
wash
phosphat
buffer
salin
pb
overlaid
fresh
vv
fb
contain
wv
seaplaqu
agaros
cambrex
bio
scienc
rockland
cell
incub
co
day
sindbi
viru
day
wnv
day
dnv
sindbi
viru
infect
quantifi
directli
count
green
fluoresc
foci
cultur
infect
denv
fix
formalin
overnight
permeabl
vv
ethanol
prior
immunostain
visual
use
human
polyclon
antiflaviviru
antibodi
gift
v
vorndam
cdc
san
juan
follow
horseradish
peroxidas
hrp
conjug
goat
antihuman
immunoglobulin
pierc
rockford
il
aec
chromogen
substrat
dako
carpinteria
ca
wnv
plaqu
similarli
visual
use
mous
antiwnv
antibodi
chemicon
temecula
ca
hrp
conjug
goat
antimous
antibodi
dako
carpinteria
ca
peptid
cytotox
measur
use
mtt
cell
prolifer
assay
r
system
minneapoli
mn
accord
manufactur
instruct
